Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 2 1

Status

Completed 8Unknown 4Withdrawn 2Terminated 2Recruiting 2Not yet recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Stomach Neoplasms 7Pancreatic Neoplasms 4Esophageal Neoplasms 2Rectal Neoplasms 1Phase I: To Determine the Maximum Tolerated Dose (MTD) 1Neoplasm Metastasis 1Nasopharyngeal Carcinoma 1Gastrointestinal Neoplasms 1Gastric Adenocarcinoma 1Colonic Neoplasms 1Biliary Tract Neoplasms 1Bile Duct Neoplasms 1

Interventions

Fluorouracil 17Cisplatin 17pembrolizumab 12Radiotherapy 11Oxaliplatin 10Irinotecan 9Paclitaxel 6Leucovorin 6Docetaxel 6Carboplatin 6Capecitabine 6Neoadjuvant Therapy 5Trastuzumab 4Panitumumab 4Gefitinib 4Esophagectomy 4Cyclophosphamide 4Cetuximab 4Surgical Procedures, Operative 3Celecoxib 3tegafur-gimeracil-oteracil 2spartalizumab 2sodium glycididazole 2niraparib 2fludarabine 2S 1 (combination) 2Plicamycin 2Pemetrexed 2Lapatinib 2Gemcitabine 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × Esophageal Neoplasms × S 1 (combination) × Clear all
NCT02216149 2018-08-28

FluoHeart

Helsinki University Central Hospital

Phase 2 Terminated
20 enrolled
Gastrointestinal

Colonic Neoplasms, Esophageal Neoplasms, Gastrointestinal Neoplasms, Rectal Neoplasms, Stomach Neoplasms

NCT01704690 2017-04-07

Combination Treatment of S-1 With Paclitaxel in Advanced Esophageal Cancer

Peking University

Phase 2/3 Terminated
4 enrolled
Gastrointestinal

Esophageal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡